What if we could make your chocolate healthier, not by removing sugar, but by encasing an enzyme that would reduce how much sugar is absorbed into the bloodstream into an edible substance added to the bar? Wyss researchers are working to develop this enzyme product that would turn sugar into fiber, which most Americans aren't getting enough of in their diet. This project, which started from a collaboration with Kraft Heinz, will hopefully find a company to bring the work to market. Read all about it in the The Wall Street Journal. Adama Marie Sesay Samuel Inverso, PhD #Collaboration #Nutrition https://lnkd.in/g4vP9Eue
Wyss Institute at Harvard University
Biotechnology Research
Boston, MA 54,916 followers
About us
At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.
- Website
-
http://wyss.harvard.edu
External link for Wyss Institute at Harvard University
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, MA
- Type
- Nonprofit
- Specialties
- Robotics, Bioengineering, Microfluidics, Medicine, Materials Science, Medical Devices, Synthetic Biology, Cell biology, Tissue engineering, Cancer research, Molecular engineering, Organ Engineering, Genome Editing, Molecular Robotics, and Immunomaterials
Locations
-
Primary
201 Brookline Ave.
Boston, MA 02215, US
Employees at Wyss Institute at Harvard University
-
Gangadhar Jogikalmath
Co-Founder Return To Vendor (RTV)
-
Ayis Antoniou
Entrepreneur/mentor/experienced, impactful, innovative leader/strategic advisor looking to connect with early-stage companies in bio-tech
-
James Gorman, M.D., Ph.D.
-
Samir Mitragotri
Professor @ Harvard University | Hiller Professor of Bioengineering | Hansjorg Wyss Professor of Biologically Inspired Engineering | Wyss Institute
Updates
-
Flow cytometry and mass cytometry have been the workhorses of many researchers analyzing single cells of the immune system and other tissues in the body. However, whereas the former is highly sensitive it lacks multiplexing potential, the latter allows highly multiplexed analysis but lacks sensitivity. ACE, a new nanotechnology developed by Peng Yin's team at the Wyss now solves this problem by enabling highly multiplexed mass cytometry that also is highly sensitive. The researchers used ACE to detect rare proteins in complex biological processes and the protein networks driving them with potential for biomedical research, biomarker discovery and drug development. Xiao-Kang Lun Kuanwei Sheng #Nanotechnology #DNA https://lnkd.in/eht_-ic3
-
-
When Clarissa May Babila was in elementary school, there was one movie she wanted to watch over and over: a PBS documentary on Rosalind Franklin. That early love for science led her to an undergraduate research position, where she realized she enjoyed learning about how a disease worked, but also wanted to do something to help patients. Now, she’s part of the Wyss Diagnostics Accelerator, using extracellular vesicles to better understand diseases like Parkinson’s and Alzheimer’s, with the eventual goal of finding a way to diagnose them earlier. Learn more about Clarissa and her work in this month’s Humans of the Wyss. https://lnkd.in/gWfBnPp6 #HOWyss #WyssDxA #BrainHealth #NeurodegenerativeDisease #Diagnostics
-
-
"In designing the eLBP, we tapped into the synthetic biology took kit that we have advanced over the past two decades and enabled Lactococcus lactis, a safe-to-use microbe, to secrete a β-lactamase enzyme that altruistically degrades β-lactams in the bacteria’s environment. The enzyme essentially becomes a ‘common good’ that cannot confer a selective advantage to the producing bacteria or be easily transferred to other bacteria, minimizing the risk and maximizing the clinical benefits of our approach." -Jim Collins #Dysbiosis #Microbiome #SyntheticBiology https://lnkd.in/gpg_RE9H
Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
https://wyss.harvard.edu
-
Catalytic converters are the most widely used kind of air pollution control device, but they are expensive and inefficient. Wyss researchers developed a new type of catalytic material that dramatically lowers the cost of cleaning air. #CleanAir #Sustainability https://lnkd.in/gEuyUxmB
Catalytic Materials: Cheaper, Better Air Purification for a Healthier World
https://wyss.harvard.edu
-
In the United States alone, an estimated 68 million people suffer from an STI. Even though most of the causative pathogens can be detected in clinical laboratories, cost, transport needs, and social barriers can hinder diagnosis. So, we need fast, accurate, and affordable diagnostic solutions. A multi-disciplinary research team at the Wyss developed a solution to this challenge by creating an enzyme-free pathogen detection platform that can target specific nucleic acid sequences and proteins. Their Crisscross Nanoseed Detection method is highly specific and ultrasensitive. #InfectiousDisease #Nanotechnology #DNA #Nanostructures https://lnkd.in/eek_3UyY
Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
https://wyss.harvard.edu
-
Cutting-edge translational research requires many things: brilliant scientists and engineers with bold ideas, state-of-the-art lab equipment and facilities, and a wide variety of materials. To amass all these innovation ingredients and more, you need to start with one thing: money. At the Wyss, we have an incredibly dedicated Sponsored Research Team to help secure grants and industry sponsored research agreements. They assist researchers in finding funding opportunities, applying, organizing necessary forms, and everything in between. Learn all about them and their work in this team spotlight. #SponsoredResearch #ResearchAdministration #Grants #IRSA #Collaboration https://lnkd.in/gKfgcZve
-
-
With an award for up to $27M from the Advanced Research Projects Agency for Health (ARPA-H), a collaborative research project at the Wyss, led by Natalie Artzi and Donald Ingber, M.D., Ph.D., will advance a disease-agnostic novel RNA therapeutic with the potential to treat diverse diseases, and to be effectively and rapidly deployable. Read more about it in the Boston Business Journal. #RNA #Therapeutics #Grants #Collaboration https://lnkd.in/eQptg_Hd
The Petri Dish: Wyss lands ARPA-H funds; Biotech grabs AbbVie drugs - Boston Business Journal
bizjournals.com
-
RNA drugs are the future of medicine, but demand is outstripping supply, largely because RNA synthesis is expensive and toxic. Wyss and Harvard Medical School researchers have created an enzyme-based synthesis method that solves these problems and enables the scale-up of RNA drugs. Read more in Genetic Engineering & Biotechnology News. #Oligonucleotides #RNA #Therapeutics https://lnkd.in/dnkHTWf9
Harvard Scientists Publish Details of Enzymatic RNA Synthesis Tech Commercialized by EnPlusOne
genengnews.com
-
Last week, the Brain Targeting Program held its annual Sponsors and Partners Meeting. The Wyss team presented their work to collaborators, and everyone had the opportunity to take part in small group discussions and a networking reception. The Wyss Brain Targeting Program is advancing brain delivery approaches that enable more safe and effective brain-targeted therapeutics. The team actively collaborates with companies and academics to tailor their brain shuttles for drug delivery of specific payloads and diseases. Learn more about the Brain Targeting Program: https://lnkd.in/e7cvHHHr #BrainTargetingProgram #Therapeutics #BloodBrainBarrier #Collaboration
-
-
-
-
-
+5
-